Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Immuneoncia Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners within 1 art unit, so the record shows examiner variation without art-unit variation.
WEIDNER, ADAM M is the busiest examiner, with 1 pending matter. Portfolio coordination can use the common art-unit setting, while each application still warrants an examiner-specific prosecution review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEIDNER, ADAM M | 1 | 63.7% | +33.6% |
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036765 | BIOMARKER FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO CANCER IMMUNOTHERAPEUTIC AGENT AND USE THEREOF | BERHANE, SELAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289696 | BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD47 AND PD-L1 | WEIDNER, ADAM M | — |
| 18036765 | BIOMARKER FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO CANCER IMMUNOTHERAPEUTIC AGENT AND USE THEREOF | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289696 | BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD47 AND PD-L1 | WEIDNER, ADAM M | 1675 | §103 | Final Rejection | — | Pending | Nov 06, 2023 |
| 18036765 | BIOMARKER FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO CANCER IMMUNOTHERAPEUTIC AGENT AND USE THEREOF | BERHANE, SELAM | 1675 | §101§103§112 | Non-Final OA | — | Pending | May 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmuneoncia Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Adam M Weidner has the most, with 1 of Immuneoncia Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
